eli lilly phase 3 trial retatrutide Lilly's triple agonist achieves 16.8% weight loss in Initial Reta Phase 3 Trials

Belo TCA, Santos GX, da Silva BEG, Rocha BLG, Abdala DW, Freire LAM, Rocha FS, Galdino G (2023) IL-10/beta-Endorphin-mediated neuroimmune modulation on Microglia during Antinociception

The practical implications are significant

By enhancing this activity, GLP-1 medications help: Delay gastric emptying, keeping you fuller for longer Improve and reduce blood sugar spikes and insulin sensitivity Suppress hunger cues and reduce cravings Although the results can be impressive, these medications shift how your body functions, especially during the first few weeks of treatment

Impact on the Brains Reward System: GLP-1 receptor agonists, like Ozempic, interact with the brains reward system, which regulates appetite and pleasure